PRF Technologies Ltd. (PRFX) NASDAQ
1.61
-0.06(-3.59%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.61
-0.06(-3.59%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2
First IPO Date
September 01, 2020
| Name | Title | Pay | Year Born |
| Efraim Cohen-Arazi | Interim CEO & Director | 0 | 1955 |
| Rita Keynan | Vice President of Pharmaceutical Operations | 287,000 | 1969 |
| Ehud Geller | Executive Chairman | 297,000 | N/A |
| Sigal Aviel | Chief Operating Officer | 341,000 | 1964 |
| Eyal Broder | Chief Financial Officer | 353,000 | 1972 |
| Stephen A. Cooper | Executive Vice President of Development | 0 | N/A |
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.